Literature DB >> 25173376

Animal models to test hiPS-derived hepatocytes in the context of inherited metabolic liver diseases.

Mathilde Dusséaux1, Sylvie Darche, Helene Strick-Marchand.   

Abstract

Human induced pluripotent stem (hiPS) cells are established following reprogramming of somatic cells from a wide variety of tissues. Given the scarcity of adult human hepatocytes, hiPS-derived hepatocytes would be a valuable source of cells to study differentiation programs, model patient-specific diseases, test drug toxicities, and cell transplantation therapies. Although hiPS-derived hepatocytes are extensively characterized in cell culture assays, testing these cells in animal models is necessary to fully evaluate their differentiation profile and their lack of tumorigenicity. Immunodeficient mouse models harboring liver damage are effective hosts in which xenogeneic hepatocytes can engraft, proliferate, and participate in liver regeneration, thus constituting a stringent test of hepatocyte functionality. The in vivo evaluation of disease-specific hiPS-derived hepatocytes should broaden our understanding of the cellular and molecular processes involved in inherited metabolic liver disease phenotypes. Herein, we detail our methods to test the functions of hiPS-derived hepatocytes in the context of the immunodeficient Rag2(-/-)IL2Rγc(-/-)Alb-uPAtg mouse model.

Entities:  

Mesh:

Year:  2014        PMID: 25173376     DOI: 10.1007/978-1-4939-1453-1_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  A novel mouse model for stable engraftment of a human immune system and human hepatocytes.

Authors:  Helene Strick-Marchand; Mathilde Dusséaux; Sylvie Darche; Nicholas D Huntington; Nicolas Legrand; Guillemette Masse-Ranson; Erwan Corcuff; James Ahodantin; Kees Weijer; Hergen Spits; Dina Kremsdorf; James P Di Santo
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 2.  Liver cell therapy: is this the end of the beginning?

Authors:  Salamah M Alwahsh; Hassan Rashidi; David C Hay
Journal:  Cell Mol Life Sci       Date:  2017-11-27       Impact factor: 9.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.